As of March 9, 2021, there were pre-purchase agreements for over three billion doses of AstraZeneca/Oxford's vaccine. This vaccine is by far the most sought after COVID-19 vaccine, especially due to its ability to be stored at normal refrigerator temperatures, while other vaccines might need ultra cold storage. Although still in phase III of clinical trials and without approval, Novavax's vaccine is the one with the second highest number of orders worldwide.

Global COVID-19 vaccine contracts At the same time, India had managed to secure around 2.2 billion COVID-19 vaccines doses, followed by the European Union which had signed pre-purchase agreements to secure nearly 1.84 billion doses of COVID-19 vaccines, while the United States already secured around 1.21 billion doses. AstraZeneca/Oxford's vaccine accounted for one billion doses of all vaccines secured by India, while also accounting for 300 million doses of all vaccines secured by the EU and the U.S., respectively.

Forecasted sales of COVID-19 vaccines As of November 2021, Comirnaty by BioNTech/Pfizer was the leading COVID-19 vaccine by forecasted sales revenue. It was expected to make around 36 billion U.S. dollars in sales revenue in 2021, followed by 29 billion dollars in 2022. Meanwhile, Spikevax by Moderna was projected to make 18 billion and 22 billion U.S. dollars in 2021 and 2022, respectively. Vaxzevria by AstraZeneca was forecasted to make 1.7 billion U.S. dollars in sales, followed by an additional 1.9 billion dollars by 2022. In contrast to most other biopharmaceutical companies, AstraZeneca had announced to sell its vaccine at almost net cost price.

As of May 2021, U.S. investor Blackrock Inc owned more than seven percent of total shares of pharmaceutical companies AstraZeneca, Pfizer, Novavax, and Johnson & Johnson, respectively. The statistic illustrates major shareholdings iat select pharmaceutical companies which are involved in the development and production of COVID-19 vaccines as of May 2021, by investor.

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in va

As of June 3, 2022, there were 1,521 drugs and vaccines in development targeting the coronavirus disease (COVID-19). American biotech company Moderna was the second ranked company worldwide with 12 drugs/vaccines in development targeting COVID-19.

This data package includes the underlying data files to replicate the calculations, charts, and tables presented in COVID-19 vaccine supply chains and the Defense Production Act, PIIE Working Paper 22-9.

If you use the data, please cite as: Bown, Chad P. (2022). COVID-19 vaccine supply chains and the Defense Production Act, PIIE Working Paper 22-9. Peterson Institute for International Economics.

Approved COVID-19 Vaccines Market Outlook

The global market size for approved COVID-19 vaccines stood at approximately USD 45 billion in 2023 and is projected to reach around USD 78 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This substantial growth is primarily driven by continuous advancements in vaccine technology, increasing global vaccination drives, and the emergence of new variants necessitating booster doses.

One of the primary growth factors for the approved COVID-19 vaccines market is the ongoing need for booster vaccinations. As new variants of the virus emerge, vaccine manufacturers are continuously enhancing existing vaccines to tackle these variants effectively. This continuous innovation ensures sustained demand for updated vaccines, thereby propelling market growth. Additionally, governments worldwide are investing heavily in vaccination programs to achieve herd immunity, further boosting market size. Initiatives like COVAX, which aim to provide equitable vaccine access, are also significant contributors to market expansion.

Another crucial factor driving market growth is the increased awareness and acceptance of vaccines among the global population. Intensive public health campaigns and educational movements have led to a higher acceptance rate of vaccines, reducing vaccine hesitancy. This trend is particularly significant in emerging economies where initial vaccine skepticism was high. The successful roll-out of initial vaccine doses has built public confidence, thereby increasing the uptake of booster doses and new vaccine variants.

The collaboration between pharmaceutical companies and governments has also played a pivotal role in the growth of the COVID-19 vaccines market. Strategic partnerships for vaccine production, distribution, and administration have streamlined the supply chain, making vaccines more accessible to the public. These collaborations have also facilitated bulk purchasing agreements, which have provided cost advantages and enhanced market penetration across various regions. Moreover, the establishment of new manufacturing facilities and the expansion of existing ones have significantly accelerated vaccine production capabilities.

The development of the COVID-19 RNA Vaccine has been a groundbreaking advancement in the fight against the pandemic. Unlike traditional vaccines, RNA vaccines work by introducing a small piece of genetic material from the virus into the body, prompting an immune response without using a live virus. This innovative approach has allowed for rapid development and deployment, significantly contributing to the global vaccination efforts. The flexibility of RNA technology also enables quick updates to the vaccine to address new variants, ensuring continued protection as the virus evolves. This adaptability has made RNA vaccines a crucial tool in achieving widespread immunity and controlling the spread of COVID-19.

Regionally, North America leads the market due to its advanced healthcare infrastructure and early adoption of vaccination programs. Europe follows closely, with significant contributions from countries like Germany, France, and the UK. The Asia Pacific region is witnessing rapid growth, driven by substantial investments in healthcare infrastructure and large-scale vaccination drives in countries like India and China. Meanwhile, Latin America and the Middle East & Africa are gradually catching up, supported by international aid and improving healthcare systems. The regional diversity ensures a balanced growth outlook for the global market.

Vaccine Type Analysis

The market for approved COVID-19 vaccines is segmented into various types, including mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, have gained significant traction due to their high efficacy rates and the rapid speed of development. The flexibility of mRNA technology to adapt swiftly to new variants has positioned them as a frontrunner in the market. This segment is expected to continue its dominance, supported by ongoing research and development activities aimed at enhancing vaccine formulations and delivery mechanisms.

Vector vaccines, which use a modified virus to deliver genetic material into cells, represent another significant segment. AstraZeneca and Johnson & Johnson are key players in t

This document provides guidance on establishment licensing, product quality and lot release to bring a COVID-19 vaccine to market in Canada.

The global COVID-19 vaccine bottle market, while experiencing a surge during the pandemic's peak, is now transitioning into a more stable, albeit still significant, phase. The market, estimated at $1.5 billion in 2025, is projected to grow at a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching approximately $2.8 billion by 2033. This sustained growth is driven by the continued need for vaccine storage and distribution infrastructure, expanding vaccination programs globally, and the increasing demand for specialized bottles capable of preserving vaccine efficacy. Key segments include scientific research centers and vaccine manufacturers, with 10-dose (20 mL) and 50-dose (100 mL) bottles holding the largest market share. North America and Europe currently dominate the market due to robust healthcare infrastructure and advanced vaccine production facilities. However, the Asia-Pacific region is expected to witness significant growth driven by increasing vaccination rates and expanding healthcare sectors in countries like India and China. The market's future trajectory will be influenced by factors such as government regulations on vaccine storage, technological advancements in bottle design (e.g., improved material properties for enhanced preservation), and the emergence of new vaccines requiring specific storage conditions. Despite the post-pandemic slowdown, several factors support continued market expansion. The ongoing need for routine childhood vaccinations and the potential for future pandemics will necessitate a consistent demand for vaccine bottles. Moreover, the growing awareness of the importance of cold chain management and vaccine safety will likely drive the adoption of more advanced and specialized bottles. The competitive landscape includes major players like Schott, Corning, NEG, and Shandong Pharmaceutical Glass Co., Ltd., each vying for market share through innovation, capacity expansion, and strategic partnerships. Regional variations in growth rates are anticipated, reflecting differing healthcare priorities and economic development levels across nations. The market's success will hinge on manufacturers' ability to adapt to evolving regulatory requirements, meet the rising demand for innovative and sustainable solutions, and navigate geopolitical and economic uncertainties.

Covid-19 Vaccine Market Outlook

The global Covid-19 vaccine market size was valued at approximately $60 billion in 2023 and is projected to reach around $90 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.5%. The increased market size is driven by the ongoing need for booster vaccinations, advancements in vaccine technology, and the rise in government and private sector investment in immunization programs. The rapid development and deployment of Covid-19 vaccines have demonstrated the potential for scientific collaboration and innovation at an unprecedented scale, which continues to fuel market growth.

One of the primary growth factors for the Covid-19 vaccine market is the continuous evolution and mutation of the SARS-CoV-2 virus. Variants such as Delta and Omicron have necessitated the development of new vaccine formulations and booster shots to maintain immunity within populations. This ongoing need for updated vaccines ensures sustained market demand. Additionally, the global effort to achieve herd immunity, particularly in regions with lower vaccination rates, continues to drive market growth as governments and health organizations strive to vaccinate the remaining unvaccinated populations.

Another significant growth factor is the advancement in vaccine technology, particularly with mRNA and vector-based vaccines. These cutting-edge technologies have shown high efficacy rates and have accelerated the vaccine development timeline. The success of Pfizer-BioNTech and Moderna mRNA vaccines has opened new avenues for vaccine research and production, not only for Covid-19 but also for other infectious diseases. This technological progress is expected to reduce production costs, enhance distribution efficiency, and increase the overall market size.

Government and private sector investment in vaccine production and distribution infrastructure has also been a crucial growth driver. Governments worldwide have allocated substantial resources to ensure widespread vaccine availability, including funding for research and development, manufacturing, and logistics. This financial backing has enabled pharmaceutical companies to expand their production capacities and streamline supply chains, ensuring that vaccines reach all corners of the globe. Moreover, public-private partnerships have played a significant role in scaling up vaccine distribution, further propelling market growth.

The introduction of Covid 19 Dna Vaccine technology marks a significant advancement in the field of immunization. Unlike traditional vaccines, DNA vaccines work by introducing a small, circular piece of DNA into the body, which encodes the antigen that triggers an immune response. This method has the potential to be more stable and easier to produce than other vaccine types, making it a promising option for rapid deployment in response to emerging variants. As research continues, DNA vaccines could play a crucial role in broadening the arsenal of tools available to combat Covid-19, offering flexibility in addressing different strains of the virus. The development of DNA vaccines is expected to complement existing vaccine technologies, enhancing the overall effectiveness of global vaccination efforts.

Regionally, the market outlook varies significantly due to differences in vaccine access, healthcare infrastructure, and governmental policies. North America and Europe have seen high vaccination rates, driven by substantial government investment and robust healthcare systems. In contrast, regions like Asia Pacific, Latin America, and Africa face challenges related to vaccine distribution and access. However, these regions also present significant growth opportunities as international organizations and governments work to improve vaccine availability and coverage. The diverse regional dynamics contribute to the overall complexity and potential of the global Covid-19 vaccine market.

Vaccine Type Analysis

The Covid-19 vaccine market is segmented by vaccine type into mRNA, vector, protein subunit, inactivated, and others. The mRNA segment, which includes vaccines such as Pfizer-BioNTech and Moderna, has dominated the market due to its high efficacy rates and rapid development timeline. mRNA vaccines have revolutionized the vaccine industry by utilizing genetic code to stimulate an immune response, leading to quicker and more effective p

GlaxoSmithKline generated approximately 9.3 billion U.S. dollars from vaccine sales in 2021, making it the sixth largest vaccine company in the world based on revenue. Before the pandemic and the appearance of COVID-19 vaccines, the British pharmaceutical giant used to be the global leader in vaccines.

Analyzing vaccine sales of leading companies GlaxoSmithKline reported an annual revenue of 34.1 billion British pounds in 2021 – vaccine sales accounted for around 20 percent of that figure. Year-on-year sales of Shingrix, the company’s shingles vaccine, more than doubled to almost two billion British pounds in 2020. The leading vaccine of Merck & Co. is Gardasil/Gardasil 9, which can help in the prevention of certain cancers. The vaccine is one of Merck’s top-selling products and accounted for more than half of the company’s total vaccine sales. Pfizer generated vaccine sales of nearly 43 billion U.S. dollars in 2021, of course heavily boosted by its COVID-19 vaccine sales. The pneumococcal vaccine Prevnar 13/Prevenar 13 was the company’s second product based on revenue during that year.

The race for a coronavirus vaccine Until recently, and despite growth in the global vaccine market, there were only four big pharma companies with substantial vaccine operations. However, the COVID-19 pandemic has highlighted the critical importance of vaccine research and development. Aided by government funding and partnerships, several smaller companies were among the first to enter the race to find vaccines and treatments for the disease. Biotech company Moderna, by applying its pioneering mRNA research to the problem, was among the first to bring a safe and effective COVID-19 vaccine to the broader market.

The global market for COVID-19 vaccine bottles experienced significant growth during the pandemic and continues to evolve. Driven by the urgent need for mass vaccination campaigns worldwide, the market witnessed a surge in demand, primarily fueled by the high volume of vaccine doses requiring safe and effective containment. The market is segmented by application (scientific research centers, vaccine manufacturers, others) and by type (10-dose and 50-dose bottles), reflecting varying needs across the pharmaceutical supply chain. Major players like Schott, Corning, NEG, Shandong Pharmaceutical Glass Co., Ltd., and Cardinal Health dominate the market, leveraging their established expertise in glass manufacturing and pharmaceutical packaging. The high CAGR (let's assume a conservative 8% for illustrative purposes, given the initial surge and subsequent stabilization) indicates continued growth, though at a more moderate pace than during the peak pandemic years. Factors like ongoing booster campaigns, the emergence of new variants requiring updated vaccines, and the growing demand for temperature-controlled packaging contribute to sustained market expansion. Regional market dominance likely reflects manufacturing capacity and vaccine production hubs, with North America and Europe initially holding substantial shares, followed by Asia-Pacific experiencing increasing growth due to expanding domestic vaccine production. However, future growth will likely be influenced by factors such as the global economic climate and the evolving landscape of infectious disease control. Market restraints include potential shifts towards alternative vaccine delivery methods, fluctuations in raw material prices (glass and other packaging components), and regulatory hurdles related to packaging standardization and safety. The continued evolution of vaccine technology also presents both opportunities and challenges; for example, new mRNA vaccines may require specific packaging solutions not previously necessary, presenting opportunities for innovation within the vaccine bottle market. Long-term projections suggest that the market will maintain a steady growth trajectory, driven by ongoing vaccination programs and potential future pandemic preparedness initiatives. Further segmentation analysis would provide a more detailed understanding of the market's evolving dynamics. For example, exploring the different types of glass used (Type I, Type II, etc.) and their relative market share could offer additional insights into technological advancement and market preferences.

The global market for vials used in COVID-19 vaccines experienced significant growth driven by the pandemic's unprecedented demand. While precise market size figures for 2019-2024 aren't provided, industry reports suggest a substantial surge during this period, followed by a more moderate, yet consistent expansion. Assuming a 2025 market size of $2 billion (a reasonable estimate considering the continued need for vaccines and related research), and a Compound Annual Growth Rate (CAGR) of 5%, the market is projected to reach approximately $2.55 billion by 2030 and $3.21 billion by 2033. This sustained growth reflects ongoing vaccine development, booster campaigns, and the potential for future pandemic preparedness. Key drivers include the increasing prevalence of vaccine-preventable diseases, technological advancements in vaccine manufacturing, and stringent regulatory frameworks ensuring vial quality and safety. The market segmentation reveals a strong demand across various applications, including vaccine manufacturing, research, and distribution. The type of glass vial used also significantly impacts market dynamics. Middle-borate borosilicate glass, offering superior chemical resistance and durability, commands a larger market share compared to low-borate options. Geographically, North America and Europe currently hold substantial market shares due to advanced healthcare infrastructure and robust vaccine manufacturing capabilities. However, the Asia-Pacific region is expected to witness accelerated growth in the coming years, driven by increasing healthcare spending and a rising population. Market restraints include price fluctuations in raw materials (like borosilicate glass) and potential supply chain disruptions. However, industry consolidation and strategic partnerships aim to mitigate these challenges and ensure a stable supply of high-quality vials for global vaccine programs.

Covid-19 Vaccine Bottle Market Outlook

The global Covid-19 vaccine bottle market size was valued at USD 1.4 billion in 2023 and is projected to reach USD 3.2 billion by 2032, growing at a CAGR of 9.2% during the forecast period. The unprecedented demand for Covid-19 vaccines has significantly fueled the growth of the vaccine bottle market worldwide. The rapid development and deployment of vaccines necessitated an equally rapid increase in the production of vaccine bottles, creating an urgent and sustained demand in this market.

One of the primary growth factors for the Covid-19 vaccine bottle market is the global vaccination drive against the Covid-19 pandemic. Governments and health organizations have been aggressively vaccinating populations to achieve herd immunity and curb the spread of the virus. This massive vaccination effort requires billions of vaccine doses, each contained within a vaccine bottle, thereby driving the market demand. Additionally, the continuous need for booster doses to enhance immunity is expected to keep the demand for vaccine bottles steady in the coming years.

Another significant growth factor is technological advancements in vaccine bottle manufacturing. Innovations such as multi-dose vials, tamper-evident designs, and improved materials that enhance the shelf-life and stability of vaccines have contributed to the market growth. These advancements not only ensure the safety and efficacy of vaccines but also facilitate more efficient vaccine distribution and administration. As manufacturers continue to develop and adopt these technologies, the market is expected to benefit from increased production capacity and efficiency.

The third key growth driver is the expansion of vaccine production facilities globally. To meet the extraordinary demand for Covid-19 vaccines, pharmaceutical companies have ramped up their production capabilities. This includes the establishment of new manufacturing plants and the expansion of existing ones. Consequently, the demand for vaccine bottles has surged, as they are a critical component in the vaccine supply chain. Moreover, international collaborations and partnerships have further bolstered production capabilities, ensuring a steady supply of vaccine bottles to meet global needs.

In the context of ensuring the safety and integrity of vaccine storage, Safety Coated Bottles have emerged as a pivotal innovation. These bottles are designed with an additional protective layer that minimizes the risk of breakage and contamination, which is crucial during the transportation and handling of vaccines. The safety coating acts as a barrier, providing an extra layer of protection against physical damage, thereby ensuring that the vaccines remain uncontaminated and effective until they reach their final destination. This innovation is particularly beneficial in high-stress environments where handling errors are more likely to occur, thus playing a vital role in maintaining the cold chain and ensuring the vaccines' efficacy.

From a regional perspective, North America and Europe are expected to lead the market due to their advanced healthcare infrastructures and significant investments in vaccine development and production. Asia Pacific is also anticipated to witness substantial growth, driven by the large population base and the increasing focus on expanding vaccination programs. Latin America and the Middle East & Africa regions are expected to experience moderate growth, supported by international aid and regional vaccination initiatives.

Material Type Analysis

The Covid-19 vaccine bottle market by material type is broadly segmented into glass and plastic. Glass vaccine bottles have been the traditional choice due to their excellent chemical resistance, durability, and impermeability. Glass bottles, particularly borosilicate glass, are favored for their ability to withstand extreme temperatures and protect the vaccine from contamination. This material's stability ensures that the vaccine's efficacy is maintained throughout its shelf life. As a result, glass bottles are highly reliable for both storage and transportation of vaccines.

In recent years, plastic vaccine bottles have gained traction due to their lightweight, shatter-resistant properties, and ease of manufacturing. Plastics such as polypropylene and polyethylene offer flexibility in design and can be produced at a lower cost compared to glass. Additionally, advancements

New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.

https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html

Moderna Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/b7pe-5nws

Janssen Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/w9zu-fywh

This document provides guidance to vaccine manufacturers seeking authorization for their vaccine that targets the SARS-CoV-2 virus. This guidance applies to applications under the interim order respecting the importation, sale and advertising of drugs for use in relation to COVID-19.

The global market for COVID-19 vaccine bottles experienced significant growth during the pandemic and continues to evolve. While precise market size figures for 2019-2024 are unavailable, the provided 5% CAGR and unspecified market size in 2025 suggest a substantial market. Considering the initial surge in vaccine production and distribution, followed by a sustained but reduced demand for booster shots and new variant-specific vaccines, we can reasonably estimate the 2025 market size to be around $500 million. This is based on the understanding that specialized glass packaging for pharmaceuticals generally represents a significant portion of total vaccine production costs and that even with reduced vaccine production, a stable demand for the specialized vials continues. The market is segmented by bottle size (10-dose and 50-dose) and application (scientific research, vaccine manufacturers, and others), reflecting differing needs across the pharmaceutical value chain. Key drivers include the continued need for vaccine storage and distribution, ongoing research and development of new vaccines, and the increasing focus on cold chain logistics. Trends suggest a movement toward more sustainable and innovative packaging solutions, including improved vial designs for enhanced stability and reduced breakage. However, market restraints include the potential for overcapacity following the initial pandemic surge and price sensitivity among some vaccine manufacturers, potentially leading to increased competition. The forecast period of 2025-2033 suggests continued growth, albeit at a moderated pace. Maintaining a conservative 5% CAGR, the market is projected to reach approximately $814 million by 2033. This growth will likely be driven by emerging infectious diseases, the continued need for pandemic preparedness, and the expansion of vaccine programs globally. Major players such as Schott, Corning, NEG, Shandong Pharmaceutical Glass Co., Ltd, and Cardinal Health dominate the market, leveraging their established manufacturing capabilities and distribution networks. Regional variations in market growth will likely be influenced by factors such as vaccine adoption rates, healthcare infrastructure development, and regulatory landscapes. North America and Europe are expected to maintain significant market share, but Asia-Pacific is expected to exhibit strong growth, fueled by increasing demand and rising healthcare spending.

Moderna records a larger-than-expected quarterly loss as demand for COVID-19 vaccines decreases, prompting a reduction in manufacturing and impacting financial performance.

CDC COVID-19 Vaccine Tracker

Cumulative and Daily Counts of COVID-19 Vaccine Doses in the United States

By Nicky Forster [source]

About this dataset

The dataset contains data points such as the cumulative count of people who have received at least one dose of the vaccine, new doses administered on a specific date, cumulative count of doses distributed in the country, percentage of population that has completed the full vaccine series, cumulative count of Pfizer and Moderna vaccine doses administered in each state, seven-day rolling averages for new doses administered and distributed, among others.

It also provides insights into the vaccination status at both national and state levels. The dataset includes information on the percentage of population that has received at least one dose of the vaccine, percentage of population that has completed the full vaccine series, cumulative counts per 100k population for both distributed and administered doses.

Additionally, it presents data specific to each state, including their abbreviation and name. It outlines details such as cumulative counts per 100k population for both distributed and administered doses in each state. Furthermore, it indicates if there were instances where corrections resulted in single-day negative counts.

The dataset is compiled from daily snapshots obtained from CDC's COVID Data Tracker. Please note that there may be reporting delays by healthcare providers up to 72 hours after administering a dose.

This comprehensive dataset serves various purposes including tracking vaccination progress over time across different locations within the United States. It can be used by researchers, policymakers or anyone interested in analyzing trends related to COVID-19 vaccination efforts at both national and state levels

How to use the dataset

• Familiarize Yourself with the Columns: Take a look at the available columns in this dataset to understand what information is included. These columns provide details such as state abbreviations, state names, dates of data snapshots, cumulative counts of doses distributed and administered, people who have received at least one dose or completed the vaccine series, percentages of population coverage, manufacturer-specific data, and seven-day rolling averages.

• Explore Cumulative Counts: The dataset includes cumulative counts that show the total number of doses distributed or administered over time. You can analyze these numbers to track trends in vaccination progress in different states or regions.

• Analyze Daily Counts: The dataset also provides daily counts of new vaccine doses distributed and administered on specific dates. By examining these numbers, you can gain insights into vaccination rates on a day-to-day basis.

• Study Population Coverage Metrics: Metrics such as pct_population_received_at_least_one_dose and pct_population_series_complete give you an understanding of how much of each state's population has received at least one dose or completed their vaccine series respectively.

• Utilize Manufacturer Data: The columns related to Pfizer and Moderna provide information about the number of doses administered for each manufacturer separately. By analyzing this data, you can compare vaccination rates between different vaccines.

• Consider Rolling Averages: The seven-day rolling average columns allow you to smooth out fluctuations in daily counts by calculating an average over a week's time window. This can help identify long-term trends more accurately.

• Compare States: You can compare vaccination progress between different states by filtering the dataset based on state names or abbreviations. This way, you can observe variations in distribution and administration rates among different regions.

• Visualize the Data: Creating charts and graphs will help you visualize the data more effectively. Plotting trends over time or comparing different metrics for various states can provide powerful visual representations of vaccination progress.

• Stay Informed: Keep in mind that this dataset is continuously updated as new data becomes available. Make sure to check for any updates or refreshed datasets to obtain the most recent information on COVID-19 vaccine distributions and administrations

Research Ideas

• Vaccination Analysis: This dataset can be used to analyze the progress of COVID-19 vaccinations in the United States. By examining the cumulative counts of doses distributed and administered, as well as the number of people who have received at least one dose or completed the vaccine series, researchers and policymakers can assess how effectively vaccines are being rolled out and monitor...

The FDA's pending decision on Novavax's COVID-19 vaccine approval raises concerns in the pharmaceutical sector, impacting stocks and future payouts.

The market is valued at USD 1,261.7 Million in 2025 and is estimated to reach USD 2,436.1 Million by 2035, growing at a CAGR of 6.8% during the forecast period.

Metric	Value
Industry Size (2025E)	USD 1,261.7 million
Industry Value (2035F)	USD 2,436.1 million
CAGR (2025 to 2035)	6.8%

Country-wise Outlook

Country	CAGR (2025 to 2035)
USA	7.1%

Country	CAGR (2025 to 2035)
UK	6.5%

Country	CAGR (2025 to 2035)
EU	6.7%

Country	CAGR (2025 to 2035)
Japan	6.4%

Country	CAGR (2025 to 2035)
South Korea	6.9%

Competitive Outlook

Company Name	Estimated Market Share (%)
Becton, Dickinson and Company (BD)	12-16%
Gerresheimer AG	10-14%
SCHOTT AG	8-12%
West Pharmaceutical Services, Inc.	6-10%
Catalent, Inc.	4-8%
Other Companies (combined)	45-55%